SAN DIEGO, March 13, 2019 /PRNewswire/ -- Epic Sciences, Inc. (Epic) today announced the publication of results from a multicenter prospective trial validating the biomarker AR-V7 (androgen receptor ...
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers In all, 142 (95%) of 150 questionnaires were completed by 38 ...
SAN DIEGO and REDWOOD CITY, Calif., March 30, 2018 /PRNewswire/ -- Epic Sciences, Inc. (Epic) and Genomic Health, Inc. (Nasdaq: GHDX) announced today that Palmetto GBA, a Medicare Administrative ...
SAN DIEGO (KGTV) -- As an active 45-year-old man who loves to surf and take adventures with his daughter, Bryce Olson was the last person his friends expected to get cancer. In 2014, a call while at ...
Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines We enrolled 118 men with mCRPC who were ...
Qiagen N.V. has announced that it is commercializing the research use only AdnaTest Prostate Cancer Panel AR-V7 to detect the androgen receptor splice variant 7 (AR-V7) from liquid biopsies to ...
* Qiagen NV - Qiagen has acquired an exclusive worldwide license from Johns Hopkins University Source text for Eikon: Further company coverage: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results